Efficacy of Linaclotide in Functional Dyspepsia and Constipation‐Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16925 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Li Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Division of Gastroenterology and Hepatology, Renji Hospit…. Hauptthemen laut MEDLINE: Constipation, Dyspepsia, Guanylyl Cyclase C Agonists, Irritable Bowel Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Aim Linaclotide is effective in relieving constipation‐predominant irritable bowel syndrome symptoms. However, few studies focus on the efficacy of linaclotide for overlapping symptoms of functional dyspepsia among irritable bowel syndrome patients. This study aimed to assess the efficacy of linaclotide compared with lactulose in patients with functional dyspepsia and constipation‐predominant irritable bowel syndrome overlap.
Methods
Seventy‐eight patient were randomized (2:1) to receive linaclotide 290 μg or lactulose 20 mL daily for 4 weeks. The primary endpoint was the overall treatment satisfaction for gastrointestinal symptom relief. The secondary endpoints included score changes in functional dyspepsia, constipation‐predominant irritable bowel syndrome symptoms, and psychological status.
Results
Seventy‐one patients (47 with linaclotide and 24 with lactulose) completed the study. A higher proportion of patients receiving linaclotide reported partial or complete relief of gastrointestinal symptoms compared with patients receiving lactulose (87.2% vs. 54.2%, p = 0.002). Dyspeptic symptoms (postprandial fullness/early satiety and bloating) and bowel symptoms (stool frequency, consistency, straining, sensation of complete evacuation, and lower abdominal discomfort) showed greater improvement in linaclotide‐treated patients than in lactulose group ( p < 0.05).
Conclusions
Linaclotide shows better efficacy for functional dyspepsia and constipation‐predominant irritable bowel syndrome overlap compared with lactulose. Trial Registration ClinicalTrials.gov : NCT05134584
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Biyu Wu, Shengliang Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cheng, L., Wang, Q., Wu, B., Yan, X., Xu, P., Qiu, H., & Chen, S. (2025). Efficacy of Linaclotide in Functional Dyspepsia and Constipation‐Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16925
Vancouver
Cheng L, Wang Q, Wu B, Yan X, Xu P, Qiu H, et al. Efficacy of Linaclotide in Functional Dyspepsia and Constipation‐Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16925
BibTeX
@article{Cheng2025,
author = {Cheng, Li and Wang, Qianqian and Wu, Biyu and Yan, Xiujuan and Xu, Ping and Qiu, Hongyi and Chen, Shengliang},
title = {Efficacy of Linaclotide in Functional Dyspepsia and Constipation‐Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16925}
}
EUVIMED